Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Pharma Mar SA ( (ES:PHM) ) has issued an update.
Pharma Mar SA, in partnership with Adium Pharma SA, has received conditional marketing approval in Argentina for Zepzelca® (lurbinectedin) to treat metastatic small cell lung cancer (SCLC) in adults. This approval, based on clinical trial data, expands the availability of lurbinectedin to 18 territories globally, highlighting its growing impact in cancer treatment markets, particularly in Latin America.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
More about Pharma Mar SA
Pharma Mar SA is a biotechnology company focused on the development and commercialization of innovative drugs, primarily targeting cancer treatment. The company is known for its marine-derived drugs and has a significant market presence in oncology.
YTD Price Performance: -1.63%
Average Trading Volume: 59,625
Technical Sentiment Signal: Buy
Current Market Cap: €1.41B
See more data about PHM stock on TipRanks’ Stock Analysis page.